Principles of signal detection in pharmacovigilance

Drug Safety

Volumn 16, Issue 6, 1997, Pages 355-365

  Meyboom, Ronald H B ^a   Egberts, Antoine C G ^a,b   Edwards, I Ralph ^c   Hekster, Yechiel A ^d   De Koning, Fred H P ^a   Gribnau, Frank W J ^d  

^a Netherlands Pharmacovigilance F   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c WHO   (Sweden)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLSTILBESTROL; ORAL CONTRACEPTIVE AGENT; PRACTOLOL; THALIDOMIDE; TRYPTOPHAN;

CLINICAL TRIAL; DATA ANALYSIS; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG TOXICITY; DRUG USE; EARLY DIAGNOSIS; EOSINOPHILIA; FOLLOW UP; HUMAN; INFORMATION PROCESSING; MORBIDITY; MUCOCUTANEOUS LYMPH NODE SYNDROME; PATIENT MONITORING; PHARMACOEPIDEMIOLOGY; PHOCOMELIA; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SIGNAL DETECTION; THROMBOEMBOLISM; VAGINA CARCINOMA; WORLD HEALTH ORGANIZATION;

EID: 0030787821     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199716060-00002     Document Type: Review

References (22)

1. Inman WHW, editor. Monitoring for drug safety. 2nd ed. Lancaster: MTP Press, 1986
2. Strom BL, editor. Pharmacoepidemiology. 2nd ed. Chichester: John Wiley, 1994
3. Irey N. Tissue reactions to drugs. Am J Pathol 1976; 82: 617-47
4. Evans SA. Causation and disease: the Henle-Koch postulates revisited. Yale J Biol Med 1976; 49: 175-95
5. Inman B. 30 years in postmarketing surveillance: a personal perspective. Pharmacoepidemiol Drug Saf 1993; 2: 239-58
6. Inman WHW. Postmarketing surveillance of adverse drug reactions in general practice. BMJ 1981; 282: 1131-2
7. Jick H. The discovery of drug-induced illness. N Engl J Med 1977; 296: 481-5
8. Davies DM, editor. Textbook of adverse drug reactions. 4th ed. Oxford: Oxford University Press, 1991
9. Edwards R, Lindquist M, Wiholm BE, et al. Quality criteria for early signals of possible adverse drug reactions. Lancet 1990; 336: 156-8
10. Coulter DM, Edwards IR, McQueen EG. New Zealand. In: Inman WHW, editor. Monitoring for drug safety. 2nd ed. Lancaster: MTP Press, 1986: 119-33
11. Dunne JF. The World Health Organization. In: Inman WHW, editor. Monitoring for drug safety. 2nd ed. Lancaster: MTP Press, 1986: 165-72
12. Wiholm BE, Olsson S, Moore N, et al. Spontaneous reporting systems outside the United States. In: Strom BL, editor. Pharmacoepidemiology. 2nd ed. Chichester: John Wiley, 1994
13. Li D, Lindquist M, Edwards IR. Evaluation of early signals of drug-induced Stevens-Johnson syndrome in the WHO ADR database. Pharmacoepidemiol Drug Saf 1992; 1: 11-8
14. Mann RD. Drug safety alerts: a review of 'Current Problems'. Pharmacoepidemiol Drug Saf 1942; 1: 269-79
15. Meyboom RHB, Gribnau FWJ, Hekster YA, et al. Characteristics of topics in pharmacovigilance in the Netherlands. Clin Drug Invest 1996; 4: 207-19
16. Finney D. Statistical logic in the monitoring of reactions to therapeutic drugs. In: Inman WHW, editor. Monitoring for drug safety. 2nd ed. Lancaster: MTP Press, 1986: 423-42
17. Gross TP. The analysis of postmarking drug surveillance data at the U.S. Food and Drug Administration. In: Strom BL, Velo G, editors. Drug epidemiology and post-marketing surveillance. New York: Plenum Press, 199: 1-7
18. Kramer MS. Clinical epidemiology and biostatistics. Berlin: Springer-Verlag, 1988
19. Charlton BG. Attribution of causation in epidemiology: chain or mozaic? J Clin Epidemiol 1996; 49: 105-7
20. Meyboom RHB, Egberts ACG, Hekster YA, et al. The role of causality assessment in pharmacovigilance. Drug Saf. In press
21. Bradford Hill A. The environment and disease: association or causation? Proc R Soc Med 1965; 85: 295-300
22. Venning GR. Identification of adverse reactions to new drugs. III: Alerting processes and early warning systems. BMJ 1983; 286: 458-60